Addendum to: Scientific Reports https://doi.org/10.1038/s41598-021-90551-6, published online 26 May 2021
In the original version of this Article we included the data reported in a preprint by Dabbous et al. entitled "Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial", which was later published1. After publication of our Article it was brought to our attention that Dabbous et al.’ paper had subsequently been retracted2. We have therefore repeated sub-analyses in which this study was originally included to establish the effect of the removal of this data from the review.
The result of the updated meta-analysis show that viral clearance 7, 10, and 14 days after hospitalization is not statistically different between the Favipiravir and control groups (RR = 1.13, 95% CI: 0.83-1.53; P = 0.425, I2 = 66.0%, P = 0.019 for 7 days; RR = 1.04, 95% CI: 0.93-1.16; P = 0.454, I2 = 0.0%, P = 0.973 for 10 days; RR = 1.11, 95% CI: 0.91-1.36; P = 0.264, I2 = 60.9%, P = 0.077 for 14 days) (Fig. 1).
Based on the updated meta-analysis, the mortality rate in the Favipiravir group was approximately 23% lower than in the control group, but this finding is not statistically significant (RR = 0.77, 95% CI: 0.26-2.19; P = 0.625, I2 = 0.0%, P = 0.585) (Fig. 2).
Dabbous, H. M. et al. RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Sci. Rep. 11, 7282 (2021).
Dabbous, H. M. et al. Retraction Note: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Sci. Rep. 11, 18983 (2021).
About this article
Cite this article
Hassanipour, S., Arab-Zozani, M., Amani, B. et al. Addendum: The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep 12, 1996 (2022). https://doi.org/10.1038/s41598-022-05835-2